Navigation Links
Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy

Recent research, which appears in the current issue of Diabetes Care, establishes Ruboxistaurin as a promising novel treatment that may improve upon established therapies for diabetic nephropathy//.

Nephropathy is known to develop in 40% of people with type 2 diabetes and is the leading cause of end-stage renal disease in the U.S. and the developed world.

Many persons with diabetes have progressive nephropathy even with the established therapies. Therefore, treatments targeting novel pathogenic mechanisms may be beneficial.

Studies have shown an important role for protein kinase C (PKC)-? in the pathogenesis of diabetic nephropathy. Ruboxistaurin selectively inhibits protein kinase C-? and ameliorates kidney disease in animal models of diabetes.

The study was performed to evaluate the effects of 32mg/day ruboxistaurin for 1 year in persons with type 2 diabetes and persistent albuminuria persistent albuminuria (albumin-to-creatinine ratio [ACR] 200-2,000 mg/g), despite therapy with renin-angiotensin system inhibitors. The primary end point was a change in the ACR. Estimated glomerular filtration rate (eGFR) was also calculated.

It was found that after one year, urinary ACR decreased significantly in participants treated with ruboxistaurin and nonsignificantly in the placebo group. The ACR-lowering effect of ruboxistaurin appeared by 1 month. eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over 1 year.

Between-group differences for changes in ACR and eGFR were not statistically significant, but this pilot study was underpowered to determine such differences.

The study authors conclude that ruboxistaurin had favorable effects on albuminuria and renal function in persons with type 2 diabetes and nephropathy. The albuminuria-lowering effect occurred early and was sustained long term. Those treated with ruboxista urin did not experience a significant decline in renal function. Ruboxistaurin may thus add benefit to established therapies for diabetic nephropathy. The authors suggest that large-scale trials should be performed to confirm its effectiveness and safety.
'"/>




Related medicine news :

1. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
2. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
3. Novel biopsy technique for prostate cancer
4. Novel computer model for breast cancer
5. Novel research on liver cancer
6. Novel way to fight cancer
7. Novel test for bowel cancer
8. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
9. Novel Therapy for Chronic Problem
10. Blood Sugar Kept In Control By Novel Protein
11. Novel antibiotic dressing developed for improved wound healing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... ... host a diverse symposium on “Doping in Sport: How the Culture Might ... Richter & Hampton LLP. The symposium will be held at Pepperdine University in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in clinical trials, today announced that Premier Research, a leading clinical development service ... Clinical trials are becoming increasingly complex, due in part to an array of ...
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... of her Smiling Patriot program today with a new Indiegogo campaign ... dental care to homeless veterans in the Los Angeles area, either as a participating ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Thomas ... perseverance and disciplined exercise regime, the author was able to successfully recover. In “ ... all relevant information for various sources on the principals of massage, anatomy , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... JOLLA, Calif. , Feb. 23, 2017 ... company leading the discovery and development of innovative medicines ... and full year 2016 financial results on Thursday, March ... will host a conference call and webcast on March ... fourth quarter and full year 2016 financial results and ...
(Date:2/23/2017)... -- ... Research and Markets has announced the addition of the "Global Antifungal ... to their offering. The Global Antifungal Drugs Market is ... decade to reach approximately $12.8 billion by 2025. ... given segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company ... and market advanced products and therapies for the Wound ... sectors of healthcare, today announced its record results for ... 2016. Full Year 2016 Highlights are: ... full year 2015 revenue ...
Breaking Medicine Technology: